Evidence map›Paper›PMID 39210558›Full record

ArticleEuropean journal of haematology2024

Idiopathic multicentric Castleman disease with marrow fibrosis and extramedullary hematopoiesis.

Marley Blommers, Sorin Selegean, Richard K Wood, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, E Ashley Wiley, Emilie Comeau, Allam A Shawwa, Stefan Rose-John, David C Fajgenbaum and 1 more

Abstract readCase Reports
In one paragraph

Article in European journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Expert Perspective: Diagnosis and Treatment of Castleman Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marley BlommersFaculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
Sorin SelegeanDepartment of Pathology, Dalhousie University.
Richard K WoodDepartment of Pathology, Dalhousie University.
Mateo Sarmiento BustamanteCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Saishravan ShyamsundarCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
E Ashley WileyDepartment of Diagnostic Radiology, Dalhousie University, Halifax, Nova Scotia, Canada.
Emilie ComeauDivision of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.
Allam A ShawwaDepartment of Pathology, Dalhousie University.
Stefan Rose-JohnBiochemical Institute, Medical Faculty, Christian-Albrechts-University, Kiel, Germany.ORCID https://orcid.org/0000-0002-7519-3279
David C FajgenbaumCenter for Cytokine Storm Treatment & Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Luke Y C ChenDivision of Hematology, Dalhousie University, Halifax, Nova Scotia, Canada.ORCID https://orcid.org/0000-0002-9551-2951

Funding

mTOR as a Central Regulator of iMCD Pathogenesis and Novel Therapeutic TargetR01HL141408 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Taku Kambayashi · 2018 to 2026
$6.1M
ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman DiseaseR01FD007632 · FDA · UNIVERSITY OF PENNSYLVANIA · PI Joshua D. Brandstadter, David C Fajgenbaum · 2022 to 2026
$2.2M
A philanthropic gift from the Hsu & Taylor Family through the VGH & UBC Hospital FoundationFDA HHS R01 FD007632NHLBI NIH HHS R01 HL141408Recordati Rare Diseasesthe National Heart, Lung, and Blood Institute
6 · The paper itself

Abstract

backgroundIdiopathic multicentric Castleman disease (iMCD) is a rare inflammatory disorder mediated by excessive proinflammatory cytokine signaling, most notably by interleukin 6 (IL-6). IL-6-induced extramedullary hematopoiesis (EMH) has been reported in murine models of iMCD. Herein we present four cases of iMCD with EMH in humans. CASE SERIES: The index case is a 24-year-old white woman who presented with pancytopenia, hepatosplenomegaly, and diffuse lymphadenopathy (LAD) with EMH in core lymph node biopsies. We then searched ACCELERATE, a Castleman disease (CD) natural history registry, and identified three additional CD cases with EMH reported in biopsies: A 23-year-old Asian man with fatigue, edema, LAD, and splenomegaly; a 20-year-old white man with fever, dyspnea, LAD, and hepatosplenomegaly; and a 50-year-old white man with constitutional symptoms, LAD, and myelodysplastic syndrome in bone marrow with a KRAS mutation.

resultsAll four patients presented with thrombocytopenia and fever and/or markedly elevated C-reactive protein. Patient 1 had iMCD-NOS (not otherwise specified) with severe thrombocytopenia, reticulin fibrosis in bone marrow, small volume LAD and organomegaly but no anasarca. The other three patients had iMCD-TAFRO (thrombocytopenia, anasarca, reticulin fibrosis, renal dysfunction, organomegaly). Two had mixed CD and two had hypervascular CD in lymph nodes. All four had bone marrow hypercellularity and megakaryocyte hyperplasia and two had reticulin fibrosis.

conclusionsThis case series demonstrates that EMH can be seen in CD, particularly in iMCD-TAFRO. Given the similarity of this finding to previous murine models of IL-6-induced marrow and lymph node changes we hypothesize that this is an IL-6-mediated phenomenon.

Indexed as

Bone MarrowCastleman DiseaseHematopoiesis, ExtramedullaryPrimary MyelofibrosisAdultBiomarkersBiopsyFemaleHumansLymph NodesMaleMiddle AgedYoung AdultBiomarkersCastleman diseaseextramedullary hematopoiesisIL‐6lymphadenopathy

Identifiers

PMID39210558
PMCPMC11537811

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.